| Code | CSB-RA005505MB1HU |
| Size | US$9799 |
| Order now | |
| Have Questions? | Leave a Message or Start an on-line Chat |
This recombinant monoclonal antibody is developed as a research-grade biosimilar to the reference antibody described in US20100111852A1, targeting claudin-3 (CLDN3), a tight junction protein critical for maintaining epithelial barrier integrity. CLDN3 is a member of the claudin family that regulates paracellular permeability and cell polarity in epithelial tissues. This protein exhibits aberrant expression patterns in various malignancies, particularly ovarian, breast, lung, and pancreatic cancers, where it often becomes overexpressed and contributes to tumor progression, metastasis, and resistance to therapy. CLDN3 has emerged as a promising biomarker and therapeutic target in oncology research due to its selective expression profile in cancer tissues.
The reference antibody has been characterized for its specific binding to CLDN3 and has demonstrated utility in cancer research applications. This biosimilar antibody provides researchers with a reliable tool for investigating CLDN3 expression patterns, exploring tight junction dynamics in normal and diseased tissues, and evaluating CLDN3 as a potential therapeutic target in various cancer models and translational studies.
There are currently no reviews for this product.